Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Information source: Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Uveitic Macular Edema; Intraocular Inflammation
Intervention: Infliximab (intravitreal, 2.0mg/0.05ml) (Drug)
Phase: Phase 1/Phase 2
Status: Withdrawn
Sponsored by: Icahn School of Medicine at Mount Sinai Official(s) and/or principal investigator(s): Farzin Forooghian, MD, Principal Investigator, Affiliation: Icahn School of Medicine at Mount Sinai
Summary
The purpose of this study is to determine if intravitreal infliximab is a safe and effective
treatment for macular edema secondary to uveitis.
Clinical Details
Official title: Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Best-corrected visual acuity
Secondary outcome: Macular thickness
Detailed description:
Participants with uveitic macular edema will be treated with one injection of intravitreal
infliximab (2. 0mg/0. 05ml) and followed for three months. Outcomes that be assessed include
best-corrected visual acuity, macular thickness as measured by optical coherence tomography,
and electroretinogram responses.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Participant must be 18 years of age or older.
2. Participant must understand and sign the protocol's informed consent document.
3. Participants must have uveitic macular edema in one eye as defined by all of the
following criteria:
1. Presence of active intermediate uveitis or posterior uveitis.
2. Macular edema defined as a central macular thickness of ≥ 250 μm on OCT.
3. Uveitis must be noninfectious as determined by standard investigations used in
the diagnostic investigation of uveitis.
4. Participant must have visual acuity between 20/40 and hand motions in the study eye.
5. Participant must have a steady fixation in the study eye and media clear enough for
good quality imaging.
6. Female participants of childbearing potential must not be pregnant or breast-feeding,
must have a negative pregnancy test at screening and must practice an adequate method
of birth control. Males able to father a child must agree to practice birth control.
Acceptable methods of birth control include hormonal contraception (birth control
pills, injected hormones or vaginal ring), intrauterine device, barrier methods with
spermicide (diaphragm with spermicide, condom and spermicide) or surgical
sterilization (hysterectomy, tubal ligation or vasectomy in a partner). If a
participant is of childbearing potential, she must be willing to undergo monthly
urine pregnancy tests. Both males and females must agree to use adequate birth
control for three months after the intravitreal infliximab injection.
Exclusion Criteria:
1. Participant is in another investigational study and actively receiving study therapy.
2. Participant is unable to comply with study procedures or follow-up visits.
3. Participant has uveitic macular edema (as defined above) in both eyes.
4. Participant has multiple sclerosis or symptoms suggestive of multiple sclerosis.
5. Participant has evidence of ocular disease other than uveitis in either eye that may
confound the outcome of the study (e. g., diabetic retinopathy, age-related macular
degeneration, vitreomacular traction, moderate/severe myopia, etc.).
6. Participant is expected to need ocular surgery in the study eye during the course of
the study.
7. Participant has undergone ocular surgery or an intravitreal/periocular steroid
injection in the study eye within the past 3 months.
8. Participant has had a YAG laser capsulotomy or intravitreal anti-VEGF treatment in
the study eye within the past 6 weeks.
9. Participant has had a pars plana vitrectomy in the study eye.
10. Participant is on ocular or systemic medications known to be toxic to the lens,
retina, or optic nerve.
11. Participant with a history of ocular herpes simplex virus infection in the study eye.
12. A condition that, in the opinion of the investigator, would preclude participation in
the study (e. g., unstable medical status including blood pressure and glycemic
control).
13. There are no criteria for inclusion/exclusion for the fellow eye. Only one eye can
have macular edema in order for the potential participant to be considered for
enrollment.
Locations and Contacts
Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York 10029, United States
Additional Information
Related publications: Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol. 2009 May;147(5):825-30, 830.e1. doi: 10.1016/j.ajo.2008.12.004. Epub 2009 Feb 10. Theodossiadis PG, Liarakos VS, Sfikakis PP, Charonis A, Agrogiannis G, Kavantzas N, Vergados IA. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2009 Feb;247(2):273-81. doi: 10.1007/s00417-008-0967-4. Epub 2008 Nov 4. Giansanti F, Ramazzotti M, Vannozzi L, Rapizzi E, Fiore T, Iaccheri B, Degl' Innocenti D, Moncini D, Menchini U. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1151-6. doi: 10.1167/iovs.07-0932. Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol. 2007 Sep;125(9):1221-4.
Starting date: August 2009
Last updated: June 21, 2011
|